Clinical Pipeline

Learn more about our pipeline

Trials for Market Approval

Download PPT

Pre-Clinical (GLP)

Sanfetrinem

GlaxoSmithKline, Bill & Melinda Gates Foundation

FNDR-20081

Foundation for Neglected Disease Research

OTB-658

Institute of Materia Medica, CAMS & PUMC

FNDR 20364

National Centre of Oceanic and Antarctic Research (NCAOR), Gao, India

TB47

Guangzhou Institute of Respiratory Medicine Company Limited, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

GSK839

GlaxoSmithKline

MBX-4888A

Microbiotix, Inc.

Phase 1

GSK-286

GlaxoSmithKline, TB Drug Accelerator, Bill & Melinda Gates Foundation

Phase 1 Safety, Tolerability and Pharmacokinetics of GSK2556286

TBAJ-587, Diarylquinoline

TB Alliance, ERA4TB (European Regimen Accelerator for Tuberculosis), University of Auckland, Merck & Co., Inc.

TBI-223

TB Alliance, Institute of Materia Medica

TBI-223 Phase 1 MAD

BVL-GSK098

BioVersys AG, GlaxoSmithKline

Phase 1 Safety, Tolerability and Pharmacokinetics of BVL-GSK098

Macozinone (MCZ, PBTZ-169)

iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation

TBAJ-876 Diarylquinoline

TB Alliance, University of Auckland

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

TBI-166

Institute of Materia Medica, CAMS & PUMC

Phase 2

Sudapyridine (WX-081)

Shanghai Jiatan Biotech Ltd., subsidiary of Guangzhou JOYO Pharma Ltd., Shanghai, China

OPC-167832

Otsuka Pharmaceutical Development & Commercialization, Inc.

OPC-167832 Phase 1 / 2 EBA

Phase 2b/c. 4-month Regimen of OPC-167832, Delamanid and Bedaquiline for DS Pulmonary TB

Sutezolid

Sequella, Inc, TB Alliance

Sutezolid Dose-finding and Combination Evaluation (SUDOCU)

BTZ-043

University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF), European and Developing Countries Clinical Trials Partnership (EDCTP), Radboud University

BTZ-043 Multiple Ascending Dose / EBA

Rifampicin

PanACEA, EDCTP, NIAID, NIH, DHHS, USAID

ReDEFINe High-Dose RIF for Meningitis

High-Dose Rifampin

Delpazolid (LCB01-0371)

LegoChem Biosciences, Inc.

A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial of LCB01-0371.

DECODE- Delpazolid Dose-Finding and Combination Development Trial

SPR720 (Fobrepodacin)

Spero Therapeutics, LLC, Bill & Melinda Gates Medical Research Institute

GSK 3036656